HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Retinol-binding protein 4 in polycystic ovary syndrome--association with steroid hormones and response to pioglitazone treatment.

AbstractCONTEXT:
Polycystic ovary syndrome (PCOS) is frequently associated with insulin resistance.
OBJECTIVE:
The aim of the study was to investigate a putative role of the adipokines retinol-binding protein 4 (RBP4), adiponectin, and visfatin in a cohort of patients with PCOS and their response to treatment with pioglitazone.
DESIGN AND SETTING:
We conducted a randomized, controlled, double-blind study at a tertiary referral center.
PATIENTS AND INTERVENTIONS:
Forty premenopausal women with PCOS were allocated to receive treatment with either pioglitazone (30 mg/d) or a placebo for a period of 3 months.
MAIN OUTCOME MEASURES:
Serum concentrations of RBP4, adiponectin, and visfatin were determined along with metabolic and hormonal parameters before and after treatment.
RESULTS:
Serum adiponectin concentrations were higher after treatment with pioglitazone (P = 0.003), whereas RBP4 levels tended to decrease (P = 0.06), and visfatin concentrations remained unchanged. We found RBP4 serum concentrations at baseline to be positively correlated with serum levels of testosterone (R = 0.446; P = 0.005), 17-OH progesterone (R = 0.345, P = 0.037), and dehydroepiandrosterone sulfate (R = 0.347; P = 0.041). However, these correlations were abolished after treatment with pioglitazone. Patients with high RBP4 levels had significantly higher hirsutism scores (P = 0.038 before and P = 0.034 after treatment). In contrast, serum adiponectin concentrations were related to parameters of impaired glucose metabolism, and no significant associations were detected for visfatin.
CONCLUSIONS:
Our results suggest that RBP4 may contribute to endocrine changes and to the phenotypic manifestation of patients with PCOS because higher RBP4 concentrations are associated with higher androgen levels and higher clinical hirsutism scores independently of pioglitazone treatment. The molecular involvement of RBP4 in human steroid metabolism requires further clarification.
AuthorsElmar Aigner, Nora Bachofner, Kerstin Klein, Christian De Geyter, Florian Hohla, Wolfgang Patsch, Christian Datz
JournalThe Journal of clinical endocrinology and metabolism (J Clin Endocrinol Metab) Vol. 94 Issue 4 Pg. 1229-35 (Apr 2009) ISSN: 1945-7197 [Electronic] United States
PMID19158194 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Adipokines
  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin
  • Placebos
  • RBP4 protein, human
  • Retinol-Binding Proteins, Plasma
  • Thiazolidinediones
  • Testosterone
  • Pioglitazone
Topics
  • Adipokines (blood)
  • Adult
  • Area Under Curve
  • Blood Glucose (metabolism)
  • Double-Blind Method
  • Female
  • Hirsutism (blood, epidemiology)
  • Humans
  • Hypoglycemic Agents (therapeutic use)
  • Insulin (blood)
  • Pioglitazone
  • Placebos
  • Polycystic Ovary Syndrome (blood, drug therapy)
  • Premenopause
  • Retinol-Binding Proteins, Plasma (drug effects, metabolism)
  • Testosterone (blood)
  • Thiazolidinediones (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: